Archives - Sunday 31 August 2008
Cell Genesys Halts VITAL-2 GVAX Trial In Advanced Prostate Cancer
Published on Sunday 31 August 2008 - 09:00 - http://www.medicalnewstoday.com/Cell Genesys, Inc. (Nasdaq:CEGE) announced that it has terminated VITAL-2, the second of two Phase 3 clinical trials of GVAX immunotherapy for prostate cancer, which compares GVAX immunotherapy in...
